Quick Takeaways
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE).
- Disclosed ownership: 10%.
- Date of event: 25 Apr 2025.
Quoteable Key Fact
"Frazier Life Sciences Public Fund, L.P. disclosed 10% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE) on 25 Apr 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 7.5% | 3,272,062 | 0 | 3,272,062 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 7.5% | 3,272,062 | 0 | 3,272,062 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 7.5% | 3,272,062 | 0 | 3,272,062 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences Public Overage Fund, L.P. | 2.2% | 965,503 | 0 | 965,503 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P. | |
| FHMLSP Overage, L.P. | 2.2% | 965,503 | 0 | 965,503 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P. | |
| FHMLSP Overage, L.L.C. | 2.2% | 965,503 | 0 | 965,503 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C. | |
| Frazier Life Sciences X, L.P. | 0.2% | 73,872 | 0 | 73,872 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. | |
| FHMLS X, L.P. | 0.2% | 73,872 | 0 | 73,872 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. | |
| FHMLS X, L.L.C. | 0.2% | 73,872 | 0 | 73,872 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.3% | 139,902 | 0 | 139,902 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.3% | 139,902 | 0 | 139,902 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.3% | 139,902 | 0 | 139,902 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C. | |
| James N. Topper | 10% | 4,451,339 | 0 | 4,451,339 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Patrick J. Heron | 10% | 4,451,339 | 0 | 4,451,339 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Albert Cha | 9.7% | 4,237,565 | 0 | 4,237,565 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| James Brush | 9.7% | 4,237,565 | 0 | 4,237,565 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| Daniel Estes | 0.3% | 139,902 | 0 | 139,902 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022 |